Integra Lifesciences (IART) Stock Statistics & Valuation Metrics

Integra Lifesciences has a market cap or net worth of $720.14M. The enterprise value is $2.52B.

Integra Lifesciences has 77,937,210 shares outstanding. The number of shares has decreased by -2.65% in one year.

Integra Lifesciences’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is 1.91%.

The current PE Ratio of Integra Lifesciences is ―. Integra Lifesciences’s PEG ratio is -0.00025.

In the last 12 months, Integra Lifesciences had revenue of 1.64B and earned -516.47M in profits. Earnings per share was -6.73.

In the last 12 months, operating cash flow was 50.38M and capital expenditures -113.29M, giving a free cash flow of -62.90M billion.

Integra Lifesciences pays an annual dividend of ―, resulting in a dividend yield of ―

Integra Lifesciences upcoming earnings date is Apr 29, 2026, Before Open (Confirmed).

Integra Lifesciences as a current ratio of 2.54, with Debt / Equity ratio of 194.85%

In the past 12 months, Integra Lifesciences has paid -47.03M in taxes.

Integra Lifesciences EV to EBITDA ratio is -8.43, with an EV/FCF ratio of -88.61.

Integra Lifesciences has $263.74M in cash and marketable securities with $2.03B in debt, giving a net cash position of -$1.77B billion.

Gross margin is 51.69%, with operating margin of 4.18%, and net profit margin of -31.58%.

The average price target for Integra Lifesciences is $11.25, which is 11.43% higher than the current price. The consensus rating is Moderate Sell